Upregulation of TNF receptor type 2 in human and experimental renal allograft rejection.
An important role of TNF interacting with TNFR2 has been shown in different models of ischemic, nephrotoxic and immune-mediated renal injury. To systematically evaluate the expression of TNFR2 in renal allograft rejection, we investigated human renal allograft biopsies and, in addition, established an experimental transplantation model in rats to verify the human data under standardized conditions. The expression of TNFR2 was analyzed in 96 human renal allograft biopsies with different disease entities. In a 6-day and a 28-day experimental protocol, TNFR2 was examined in kidney specimens and in the urine of control, uni-nephrectomized and transplanted rats +/- cyclosporine treatment (n = 114). In human biopsies and in rat allografts on day 6 with acute allograft rejection, significantly elevated expression of TNFR2 was observed in tubular epithelial cells, podocytes, B cells and monocytes/macrophages. The expression level was associated with renal function. The TNFR2 expression level at day 28 was significantly lower compared to day 6. TNFR2 is markedly upregulated both in human and experimental acute renal allograft rejection. Our data are robust and consistent between different species, suggesting a role for TNFR2 in the early course of rejection.
Hoffmann
U
U
Department of Internal Medicine II, University of Regensburg, Regensburg, Germany. Ute.hoffmann@klinik.uni-regensburg.de
Bergler
T
T
Rihm
M
M
Pace
C
C
Krüger
B
B
Rümmele
P
P
Stoelcker
B
B
Banas
B
B
Männel
D N
DN
Krämer
B K
BK
D000328:Adult; D000368:Aged; D000818:Animals; D001706:Biopsy; D016572:Cyclosporine / Q000627:therapeutic use; D005260:Female; D005786:Gene Expression Regulation; D006084:Graft Rejection / Q000235:genetics*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D023421:Models, Animal; D051381:Rats; D047888:Receptors, Tumor Necrosis Factor, Type I / Q000502:physiology; D047889:Receptors, Tumor Necrosis Factor, Type II / Q000235:genetics*; D014184:Transplantation, Homologous / Q000473:pathology; D015854:Up-Regulation
D007166:Immunosuppressive Agents; D047888:Receptors, Tumor Necrosis Factor, Type I; D047889:Receptors, Tumor Necrosis Factor, Type II; D016572:Cyclosporine